Targeting myocardial inflammation: investigating the therapeutic potential of atrial natriuretic peptide in atrial fibrosis

• Published in: Molecular biology reports Vol. 51; no. 1; p. 506
• Main Authors: Zhu, Nana, Li, Tianlun, Bai, Yili, Sun, Jiao, Guo, Jianping, Yuan, Hongtao, Shan, Zhaoliang
• Format: Journal Article
• Language: English
• Published: Dordrecht Springer Netherlands 01.12.2024; Springer Nature B.V
• Subjects: 1-Phosphatidylinositol 3-kinase; AKT protein; Angiotensin; Angiotensin II; Angiotensin II - pharmacology; Animal Anatomy; Animal Biochemistry; Animals; Atrial Fibrillation - drug therapy; Atrial Natriuretic Factor - metabolism; Atrial Natriuretic Factor - pharmacology; Atrial natriuretic peptide; Biomedical and Life Sciences; Blood pressure; Body weight; Collagen; Fibrosis; Histology; Inflammation; Inflammation - drug therapy; Interleukin 6; Life Sciences; Macrophages; Morphology; Original; Original Article; Peptides; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Signal transduction; Tenascin; Tenascin C; Transcriptomics; Inflammation; ANP; Atrial fibrosis; Atrial fibroblasts; Tenascin-C
• ISSN: 0301-4851; 1573-4978
• DOI: 10.1007/s11033-024-09393-w

Background Atrial Fibrillation (AF), a prevalent arrhythmic condition, is intricately associated with atrial fibrosis, a major pathological contributor. Central to the development of atrial fibrosis is myocardial inflammation. This study focuses on Atrial Natriuretic Peptide (ANP) and its role in mitigating atrial fibrosis, aiming to elucidate the specific mechanisms by which ANP exerts its effects, with an emphasis on fibroblast dynamics. Methods and results The study involved forty Sprague-Dawley rats, divided into four groups: control, Angiotensin II (Ang II), Ang II + ANP, and ANP only. The administration of 1 µg/kg/min Ang II was given to Ang II and Ang II + ANP groups, while both Ang II + ANP and ANP groups received 0.1 µg/kg/min ANP intravenously for a duration of 14 days. Cardiac fibroblasts were used for in vitro validation of the proposed mechanisms. The study observed that rats in the Ang II and Ang II + ANP groups showed an increase in blood pressure and a decrease in body weight, more pronounced in the Ang II group. Diastolic dysfunction, a characteristic of the Ang II group, was alleviated by ANP. Additionally, ANP significantly reduced Ang II-induced atrial fibrosis, myofibroblast proliferation, collagen overexpression, macrophage infiltration, and the elevated expression of Interleukin 6 (IL-6) and Tenascin-C (TN-C). Transcriptomic sequencing indicated enhanced PI3K/Akt signaling in the Ang II group. Furthermore, in vitro studies showed that ANP, along with the PI3K inhibitor LY294002, effectively reduced PI3K/Akt pathway activation and the expression of TN-C, collagen-I, and collagen-III, which were induced by Ang II. Conclusions The study demonstrates ANP’s potential in inhibiting myocardial inflammation and reducing atrial fibrosis. Notably, ANP’s effect in countering atrial fibrosis seems to be mediated through the suppression of the Ang II-induced PI3K/Akt-Tenascin-C signaling pathway. These insights enhance our understanding of AF pathogenesis and position ANP as a potential therapeutic agent for treating atrial fibrosis.